Share on StockTwits

Zogenix (NASDAQ:ZGNX) Director Cam L. Garner bought 30,000 shares of the stock in a transaction dated Friday, June 13th. The shares were purchased at an average cost of $1.66 per share, with a total value of $49,800.00. Following the completion of the purchase, the director now directly owns 326,750 shares in the company, valued at approximately $542,405. The transaction was disclosed in a document filed with the SEC, which is available at this link.

ZGNX has been the subject of a number of recent research reports. Analysts at R. F. Lafferty initiated coverage on shares of Zogenix in a research note on Friday, June 6th. They set a “buy” rating and a $3.50 price target on the stock. They noted that the move was a valuation call. Separately, analysts at William Blair reiterated an “outperform” rating on shares of Zogenix in a research note on Monday, May 12th. They now have a $5.00 price target on the stock, down previously from $6.00. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Zogenix in a research note on Friday, April 25th. They now have a $5.00 price target on the stock.

Shares of Zogenix (NASDAQ:ZGNX) traded up 4.85% on Monday, hitting $1.73. 1,934,916 shares of the company’s stock traded hands. Zogenix has a 52-week low of $1.38 and a 52-week high of $5.19. The stock’s 50-day moving average is $2.17 and its 200-day moving average is $3.25. The company’s market cap is $241.4 million.

Zogenix (NASDAQ:ZGNX) last announced its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $7.70 million for the quarter, compared to the consensus estimate of $8.71 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, analysts predict that Zogenix will post $-0.64 earnings per share for the current fiscal year.

Zogenix, Inc (NASDAQ:ZGNX) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.